UK markets close in 4 hours 36 minutes
  • FTSE 100

    7,882.50
    +45.79 (+0.58%)
     
  • FTSE 250

    20,311.84
    -97.54 (-0.48%)
     
  • AIM

    881.39
    -2.40 (-0.27%)
     
  • GBP/EUR

    1.1195
    -0.0011 (-0.10%)
     
  • GBP/USD

    1.1988
    -0.0036 (-0.30%)
     
  • BTC-GBP

    19,183.17
    +37.93 (+0.20%)
     
  • CMC Crypto 200

    528.50
    +3.36 (+0.64%)
     
  • S&P 500

    4,111.08
    -25.40 (-0.61%)
     
  • DOW

    33,891.02
    -34.99 (-0.10%)
     
  • CRUDE OIL

    75.36
    +1.25 (+1.69%)
     
  • GOLD FUTURES

    1,880.00
    +0.50 (+0.03%)
     
  • NIKKEI 225

    27,685.47
    -8.18 (-0.03%)
     
  • HANG SENG

    21,298.70
    +76.54 (+0.36%)
     
  • DAX

    15,315.16
    -30.75 (-0.20%)
     
  • CAC 40

    7,137.48
    +0.38 (+0.01%)
     

The Biotech Growth Trust Plc - Transaction in Own Shares

For immediate release

20 January 2023

THE BIOTECH GROWTH TRUST PLC

(the "Company")

MARKET PURCHASE OF COMPANY’S OWN SHARES

Notification is given, pursuant to the authority granted at Annual General Meeting of the Company held on 19 July 2022 to make market purchases of the Company’s own shares up to an aggregate maximum of 6,134,167 that a market total of 73,306 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 936.05 pence per share.

Following this transaction and in conformity with the provisions of the Transparency Directive, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company is 39,909,537. The Company does not currently hold any Ordinary shares in treasury.

The figure of 39,909,537 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

For and on behalf of

Frostrow Capital LLP

Company Secretary

For further information, please contact:

Mark Pope

Frostrow Capital LLP

Tel: 020 3 170 4913